Noll L Campbell

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6670549/publications.pdf

Version: 2024-02-01

71 papers

3,868 citations

172386 29 h-index 60 g-index

75 all docs

75 docs citations

75 times ranked 4185 citing authors

#	Article	IF	CITATIONS
1	Impact of anticholinergics on the aging brain: a review and practical application. Aging Health, 2008, 4, 311-320.	0.3	531
2	The cognitive impact of anticholinergics: A clinical review. Clinical Interventions in Aging, 2009, 4, 225.	1.3	356
3	Anticholinergic drugs and risk of dementia: case-control study. BMJ: British Medical Journal, 2018, 361, k1315.	2.4	314
4	Effect of medications with anti-cholinergic properties on cognitive function, delirium, physical function and mortality: a systematic review. Age and Ageing, 2014, 43, 604-615.	0.7	269
5	Medication Adherence in Older Adults With Cognitive Impairment: A Systematic Evidence-Based Review. American Journal of Geriatric Pharmacotherapy, 2012, 10, 165-177.	3.0	167
6	Risk Factors for the Progression of Mild Cognitive Impairment to Dementia. Clinics in Geriatric Medicine, 2013, 29, 873-893.	1.0	154
7	Longâ€ŧerm anticholinergic use and the aging brain. Alzheimer's and Dementia, 2013, 9, 377-385.	0.4	146
8	The Confusion Assessment Method for the ICU-7 Delirium Severity Scale: A Novel Delirium Severity Instrument for Use in the ICU. Critical Care Medicine, 2017, 45, 851-857.	0.4	140
9	Pharmacological Management of Delirium in Hospitalized Adults – A Systematic Evidence Review. Journal of General Internal Medicine, 2009, 24, 848-853.	1.3	122
10	Impact and recognition of cognitive impairment among hospitalized elders. Journal of Hospital Medicine, 2010, 5, 69-75.	0.7	113
11	Delirium in hospitalized patients: Implications of current evidence on clinical practice and future avenues for researchâ€"A systematic evidence review. Journal of Hospital Medicine, 2012, 7, 580-589.	0.7	94
12	Biomarkers for Delirium—A Review. Journal of the American Geriatrics Society, 2011, 59, S256-61.	1.3	81
13	Comparison and Agreement Between the Richmond Agitation-Sedation Scale and the Riker Sedation-Agitation Scale in Evaluating Patients' Eligibility for Delirium Assessment in the ICU. Chest, 2012, 142, 48-54.	0.4	75
14	Biomarkers of Delirium Duration and Delirium Severity in the ICU*. Critical Care Medicine, 2020, 48, 353-361.	0.4	74
15	Association of Anticholinergic Burden with Cognitive Impairment and Health Care Utilization Among a Diverse Ambulatory Older Adult Population. Pharmacotherapy, 2016, 36, 1123-1131.	1.2	73
16	A review of published anticholinergic scales and measures and their applicability in database analyses. Archives of Gerontology and Geriatrics, 2020, 87, 103885.	1.4	69
17	Association Between Prescribing of Anticholinergic Medications and Incident Delirium: A Cohort Study. Journal of the American Geriatrics Society, 2011, 59, S277-81.	1.3	62
18	Impact of cholinesterase inhibitors on behavioral and psychological symptoms of Alzheimer's disease: A meta-analysis. Clinical Interventions in Aging, 2008, Volume 3, 719-728.	1.3	61

#	Article	IF	Citations
19	Enhancing Care for Hospitalized Older Adults with Cognitive Impairment: A Randomized Controlled Trial. Journal of General Internal Medicine, 2012, 27, 561-567.	1.3	55
20	Association between cumulative anticholinergic burden and falls and fractures in patients with overactive bladder: US-based retrospective cohort study. BMJ Open, 2019, 9, e026391.	0.8	53
21	Anticholinergics Influence Transition from Normal Cognition to Mild Cognitive Impairment in Older Adults in Primary Care. Pharmacotherapy, 2018, 38, 511-519.	1.2	49
22	Effect of mirabegron on cognitive function in elderly patients with overactive bladder: MoCA results from a phase 4 randomized, placebo-controlled study (PILLAR). BMC Geriatrics, 2020, 20, 109.	1.1	45
23	Usability and feasibility of consumer-facing technology to reduce unsafe medication use by older adults. Research in Social and Administrative Pharmacy, 2020, 16, 54-61.	1.5	42
24	Development of core outcome sets for effectiveness trials of interventions to prevent and/or treat delirium (Del-COrS): study protocol. BMJ Open, 2017, 7, e016371.	0.8	40
25	Adherence and Tolerability of Alzheimer's Disease Medications: A Pragmatic Randomized Trial. Journal of the American Geriatrics Society, 2017, 65, 1497-1504.	1.3	39
26	Anticholinergic and benzodiazepine medication use and risk of incident dementia: a UK cohort study. BMC Geriatrics, 2019, 19, 276.	1.1	39
27	Pharmacological Management of Delirium in the Intensive Care Unit: A Randomized Pragmatic Clinical Trial. Journal of the American Geriatrics Society, 2019, 67, 1057-1065.	1.3	37
28	Aging and Post–Intensive Care Syndrome: A Critical Need for Geriatric Psychiatry. American Journal of Geriatric Psychiatry, 2018, 26, 212-221.	0.6	35
29	Association of anticholinergic medications and AD biomarkers with incidence of MCI among cognitively normal older adults. Neurology, 2020, 95, e2295-e2304.	1.5	32
30	One‥ear Effect of the Medicare Annual Wellness Visit on Detection of Cognitive Impairment: A Cohort Study. Journal of the American Geriatrics Society, 2018, 66, 969-975.	1.3	31
31	Preventing Postoperative Delirium After Major Noncardiac Thoracic Surgery—A Randomized Clinical Trial. Journal of the American Geriatrics Society, 2018, 66, 2289-2297.	1.3	30
32	Deprescribing in the Pharmacologic Management of Delirium: A Randomized Trial in the Intensive Care Unit. Journal of the American Geriatrics Society, 2019, 67, 695-702.	1.3	30
33	History of Benzodiazepine Prescriptions and Risk of Dementia: Possible Bias Due to Prevalent Users and Covariate Measurement Timing in a Nested Case-Control Study. American Journal of Epidemiology, 2019, 188, 1228-1236.	1.6	28
34	Understanding older adults' medication decision making and behavior: A study on over-the-counter (OTC) anticholinergic medications. Research in Social and Administrative Pharmacy, 2019, 15, 53-60.	1.5	28
35	Improving delirium care in the intensive care unit: The design of a pragmatic study. Trials, 2011, 12, 139.	0.7	25
36	Relationship Between African-American Race and Delirium in the ICU. Critical Care Medicine, 2016, 44, 1727-1734.	0.4	24

3

#	Article	IF	Citations
37	Selfâ€Reported Medication Adherence Barriers Among Ambulatory Older Adults with Mild Cognitive Impairment. Pharmacotherapy, 2016, 36, 196-202.	1.2	23
38	A Core Outcome Set for Research Evaluating Interventions to Prevent and/or Treat Delirium in Critically III Adults: An International Consensus Study (Del-COrS). Critical Care Medicine, 2021, 49, 1535-1546.	0.4	21
39	Anticholinergic Exposure During Rehabilitation: Cognitive and Physical Function Outcomes in Patients with Delirium Superimposed on Dementia. American Journal of Geriatric Psychiatry, 2015, 23, 1250-1258.	0.6	20
40	Caregiverâ€Based Interventions to Optimize Medication Safety in Vulnerable Elderly Adults: A Systematic Evidenceâ€Based Review. Journal of the American Geriatrics Society, 2018, 66, 2128-2135.	1.3	19
41	Going Remote—Demonstration and Evaluation of Remote Technology Delivery and Usability Assessment With Older Adults: Survey Study. JMIR MHealth and UHealth, 2021, 9, e26702.	1.8	19
42	Connecting research discovery with care delivery in dementia: the development of the Indianapolis Discovery Network for Dementia. Clinical Interventions in Aging, 2012, 7, 509.	1.3	16
43	Reporting of Outcomes and Outcome Measures in Studies of Interventions to Prevent and/or Treat Delirium in the Critically III: A Systematic Review. Critical Care Medicine, 2020, 48, e316-e324.	0.4	15
44	Recommendations for outcome measurement for deprescribing intervention studies. Journal of the American Geriatrics Society, 2022, 70, 2487-2497.	1.3	15
45	Multicomponent behavioral intervention to reduce exposure to anticholinergics in primary care older adults. Journal of the American Geriatrics Society, 2021, 69, 1490-1499.	1.3	14
46	Update on Pharmacotherapy for Prevention and Treatment of Post-operative Delirium: A Systematic Evidence Review. Current Anesthesiology Reports, 2015, 5, 57-64.	0.9	13
47	Adverse Cognitive Effects of Medications. JAMA Internal Medicine, 2015, 175, 408.	2.6	13
48	Race and Documentation of Cognitive Impairment in Hospitalized Older Adults. Journal of the American Geriatrics Society, 2014, 62, 506-511.	1.3	12
49	A core outcome set for studies evaluating interventions to prevent and/or treat delirium for adults requiring an acute care hospital admission: an international key stakeholder informed consensus study. BMC Medicine, 2021, 19, 143.	2.3	10
50	Usability-In-Placeâ€"Remote Usability Testing Methods for Homebound Older Adults: Rapid Literature Review. JMIR Formative Research, 2021, 5, e26181.	0.7	10
51	Characterization of hepatic enzyme activity in older adults with dementia: potential impact on personalizing pharmacotherapy. Clinical Interventions in Aging, 2015, 10, 269.	1.3	9
52	Estimated Budget Impact of Increased Use of Mirabegron, A Novel Treatment for Overactive Bladder. Journal of Managed Care & Decialty Pharmacy, 2016, 22, 1072-1084.	0.5	9
53	Fall/Fracture-Related Healthcare Costs and Their Association with Cumulative Anticholinergic Burden in People with Overactive Bladder. PharmacoEconomics - Open, 2021, 5, 45-55.	0.9	9
54	Medication adherence and tolerability of Alzheimer"; $\frac{1}{2}$ s disease medications: study protocol for a randomized controlled trial. Trials, 2013, 14, 125.	0.7	8

#	Article	IF	CITATIONS
55	Preventing Alzheimer Disease by Deprescribing Anticholinergic Medications. JAMA Internal Medicine, 2019, 179, 1093.	2.6	8
56	Helping the Helpers – A research protocol for user-centered technology to aid caregiver management of medications for people with Alzheimer's disease and related dementias. Research in Social and Administrative Pharmacy, 2022, 18, 3680-3686.	1.5	8
57	Reducing anticholinergic medication exposure among older adults using consumer technology: Protocol for a randomized clinical trial. Research in Social and Administrative Pharmacy, 2021, 17, 986-992.	1.5	7
58	Long-term evaluation of a train-the-trainer workshop for pharmacy faculty using the RE-AIM framework. Research in Social and Administrative Pharmacy, 2021, 17, 1562-1569.	1.5	6
59	Deprescribing opportunities for elderly inpatients in an academic, safety-net health system. Research in Social and Administrative Pharmacy, 2021, 17, 541-544.	1.5	5
60	A 12-Year Retrospective Study of the Prevalence of Anticholinergic Polypharmacy and Associated Outcomes Among Medicare Patients with Overactive Bladder in the USA. Drugs and Aging, 2021, 38, 1075-1085.	1.3	5
61	An Evaluation of Longitudinal Measures of Anticholinergic Exposure for Application in Retrospective Administrative Data Analyses. Advances in Therapy, 2019, 36, 2247-2259.	1.3	4
62	Deprescribing Anticholinergics in Primary Care Older Adults: Experience from Two Models and Impact on a Continuous Measure of Exposure. JACCP Journal of the American College of Clinical Pharmacy, 0,	0.5	3
63	Neuropathological Correlates of Cumulative Benzodiazepine and Anticholinergic Drug Use. Journal of Alzheimer's Disease, 2020, 74, 999-1009.	1.2	2
64	Human-Centered Design and Research in Deprescribing. Proceedings of the Human Factors and Ergonomics Society, 2021, 65, 398-402.	0.2	1
65	P4-303: A randomized trial of the adherence and tolerability of acetylcholinesterase inhibitors. , 2015, 11, P901-P901.		o
66	P1-066: Tolerability of Acetylcholinesterase Inhibitors by CYP2D6 Activity., 2016, 12, P427-P427.		0
67	[P3–555]: ANTICHOLINERGICS INFLUENCE TRANSITION FROM NORMAL COGNITION TO MCI IN PRIMARY CARE OLDER ADULTS. Alzheimer's and Dementia, 2017, 13, P1191.	0.4	O
68	The Case for Human-Centered Research on the Complex Patient Journey of Deprescribing. Proceedings of the International Symposium of Human Factors and Ergonomics in Healthcare, 2021, 10, 276-280.	0.2	0
69	Medication-Related Problems in Surgical Patients. , 2018, , 1-29.		О
70	Medication-Related Problems in Surgical Patients. , 2020, , 159-187.		0
71	Treatment Strategies for Delirium. , 2020, , 209-221.		O